中国临床药理学杂志2017，Vol.33Issue(19)：1878-1881,4.DOI:10.13699/j.cnki.1001-6821.2017.19.008
雷公藤多苷治疗IgA肾病患者的临床研究
Clinical trial of tripterygium wilfordii polyglycoside in the treatment of patients with IgA nephropathy
摘要
Abstract
Objective To study the clinical efficacy of tripterygium glycosides in the treatment of IgA nephropathy.Methods Forty patients with IgA nephropathy admitted were enrolled in this study.The patient were treated with tripterygium glycosides 1 mg · kg-1 · d-1,three times orally,were treated for 6 months.Another 40 healthy subjects in the hospital for the same period as the control group,the control group did not do any treatment.Serum interleukin-15 (IL-15) and interleukin-18 (IL-18) levels were measured by enzyme-linked immunosorbent assay (ELISA).The clinical efficacy of the patients was analyzed,and the quantitative indexes of blood lipid and 24 h urine protein were determined.Results After treatment,the total effective rate of the treatment group was 90.00％ (36/40 cases).Before treatment,the levels of serum IL-15 and IL-18 in the treatment group and the control group were (79.47±7.46),(344.14 ±21.49) ng· L-1;(61.91 ±4.88),(95.70 ± 6.78) ng · L-1.Compared with the control group,the difference was statistically significant (all P ＜0.05).After treatment,the levels of serum IL-15 and IL-18 in the treatment group was (61.76 ± 6.98) and (94.49 ± 8.73) ng · L-1 respectively,compared with control group,there was no significant difference between the two groups (P ＞ 0.05).Before treatment,urine red blood cell(RBC) count and 24 h urinary protein in the treatment group and the control group were (153.00 ± 10.33),(101.30 ± 7.67) per · μL-1;(1.99 ± 0.17),(0.48 ± 0.04) g · d-1.Compared with the control group,the differences were statistically significant (all P ＜ 0.05).After treatment,urine RBC count and 24 h urinary protein in the treatment group were(103.16 ± 7.54) per · μL-1,(0.51 ± 0.04) g · d-1.Compared with before treatment,the differences were statistically significant (all P ＜ 0.05).Compared with the control group,the difference was not statistically significant (P ＞ 0.05).Conclusion Tripterygium glycosides for IgA nephropathy,can effectively reduce the serum IL-15,IL-18 levels,improve the clinical symptoms of patients,and good safety.关键词
雷公藤多苷/IgA肾病/白细胞介素-15/白细胞介素-18Key words
tripterygium glycosides/IgA nephropathy/interleukin-15/interleukin-18分类
医药卫生引用本文复制引用
沈世忠,杨忠民,蔡佳盈,孙凌云,胡义阳,王捷..雷公藤多苷治疗IgA肾病患者的临床研究[J].中国临床药理学杂志,2017,33(19):1878-1881,4.基金项目
泉州市科技计划基金资助项目(2014Z66) （2014Z66）
